### Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Andreotti Felicita      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Pfizer (see also BMS) : apixaban (2012-2013)  
- BMS-Pfizer : apixaban, cardiovascular metabolism (2012-2013)  
- Bayer Schering Pharma : aspirin, rivaroxaban (2012-2013-2014)  
- Eli Lilly : prasugrel (2012-2013-2014)  
- Daiichi Sankyo : edoxaban (2012-2014)  
- Daiichi Sankyo-Eli Lilly : edoxaban, prasugrel (2013)  
- Pfizer : apixaban (2014)  
- BMS : apixaban, cardiovascular metabolism (2014)  
- Boehringer-Ingelheim : non-vitamin k antagonist oral anticoagulants (2015)  
- Daiichi Sankyo : non-vitamin k antagonist oral anticoagulants (2015)  
- Pfizer : non-vitamin k antagonist oral anticoagulants (2015)  
- BMS-Pfizer : non-vitamin k antagonist oral anticoagulants (2015)                                                                                                                                 |
| Bax Jeroen              | Nothing to be declared (2014-2015)  
D - Research funding (departmental or institutional).  
- Servier : Farma (2012-2013)  
- Edwards Lifesciences : Heart Valves (2012-2013)  
- GE Healthcare : Imaging (2012-2013)  
- Lantheus Inc : Imaging (2012-2013)  
- Boston Scientific : Pacing (2012-2013)  
- Medtronic : Pacing (2012-2013)  

27/08/2015
Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bax Jeroen</td>
<td>- St Jude Medical : Pacing (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Biotronik : Pacing (2012-2013)</td>
</tr>
<tr>
<td>Borger Michael A</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td>Brotons Carlos</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Brilipta (2014)</td>
</tr>
<tr>
<td>Chew Derek</td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Anti-platelet therapy (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott Vascular : Mitral Clip (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Anti-platelet therapy (2012-2013)</td>
</tr>
<tr>
<td>Collet Jean-Philippe</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : antiplatelet (2012)</td>
</tr>
<tr>
<td></td>
<td>- Eli Lilly : antiplatelet (2012)</td>
</tr>
<tr>
<td></td>
<td>- Medco Health Solutions : antiplatelet (2012)</td>
</tr>
</tbody>
</table>
### Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Collet Jean-Philippe | - Accumetrics : antiplatelet agents (2012)  
- Bristol Myers Squibb : antiplatelet and anticoagulant (2012)  
- Medtronic : valves (2012)  
D - Research funding (departmental or institutional).  
- Eli Lilly : prasugrel (2013)  
| Hasenfuss Gerd       | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- CVRx : Baroreceptor stimulator (2012)  
- CVRx : Baroreceptor Stimulation (2015) |
### Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hasenfuss Gerd</td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Circulite : Assist Device (2012)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Brilique (2012)</td>
</tr>
<tr>
<td></td>
<td>- Bayer : rivaroxaban (2012)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Servier : RYCALS (2012)</td>
</tr>
<tr>
<td>Kjeldsen Keld Per</td>
<td>Nothing to be declared (2012-2013-2014-2015)</td>
</tr>
<tr>
<td>Lancellotti Patrizio</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Boston Scientific : Heart Failure (2012)</td>
</tr>
<tr>
<td></td>
<td>- Servier : Heart Failure (2013)</td>
</tr>
<tr>
<td></td>
<td>- Menarini : nebivolol (2014)</td>
</tr>
<tr>
<td></td>
<td>- St Jude Medical : Heart Failure (2015)</td>
</tr>
<tr>
<td></td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Brilique (2012)</td>
</tr>
<tr>
<td></td>
<td>- Servier : Coversyl (2012)</td>
</tr>
<tr>
<td></td>
<td>- Astrazeneca : Dyslipidemia (2013)</td>
</tr>
<tr>
<td></td>
<td>- Boston Scientific : CRT (2014)</td>
</tr>
<tr>
<td></td>
<td>- Servier : procoralan (2014)</td>
</tr>
<tr>
<td></td>
<td>- Daiichi Sankyo : Teaching course on imaging (2015)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Actelion : Pulmonary Hypertension (2013)</td>
</tr>
<tr>
<td>Landmesser Ulf</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Sanofi Aventis : Cardiovascular Research (2012)</td>
</tr>
<tr>
<td></td>
<td>- Roche Pharma : Cardiovascular Research (2012-2013)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Roche Pharma : Research grant, Advisory Board (2014-2015)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : Research grant, Speakers fee (2014-2015)</td>
</tr>
<tr>
<td>Mehilli Julinda</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Roche Diagnostics : Antithrombotic drugs (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Lilly/Daiichi Sankyo : Antithrombotic drugs (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Biotronik : PCI (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Terumo Inc : PCI (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott Vascular : PCI (2012-2013)</td>
</tr>
<tr>
<td>Mueller Christian Eugen</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Alere : Diagnostics (2012)</td>
</tr>
</tbody>
</table>
Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>D - Research funding (departmental or institutional).</td>
<td>- Medicines Company : Acute Heart Failure (2012)</td>
</tr>
<tr>
<td></td>
<td>- Swiss Heart Foundation : Diagnostics (2012)</td>
</tr>
<tr>
<td></td>
<td>- Beckman Coulter : Diagnostics (2012)</td>
</tr>
<tr>
<td></td>
<td>- Nanosphere : Diagnostics (2012)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Mukherjee Debabrata | C - Receipt of royalties for intellectual property.  
| Patrono Carlo      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Astra Zeneca : Ticagrelor, PPI (2012)  
- Bayer : Aspirin (2012-2013)  
- Eli Lilly : Prasugrel (2012-2013)  
- Merck Sharp & Dohme : Vorapaxar (2012-2013)  
D - Research funding (departmental or institutional).  
| Roffi Marco        | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Daiichi Sankyo : antiplatelet therapy (2012-2013)  
- Lilly : antiplatelet therapy (2012-2013)  
- Astra Zeneca : antiplatelet therapy (2012-2013)  
- Johnson & Johnson : coronary catheters (2014)  
D - Research funding (departmental or institutional).  
| Storey Robert      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Eisai : Atopaxar (2012)  
- Bristol Myers Squibb : Clopidogrel (2012)  
- Sanofi Aventis : Clopidogrel/PCSK9 inhibitor/otamixaban (2012) |
## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
                        - Daiichi Sankyo: Prasugrel (2012)  
                        - Eli Lilly: Prasugrel (2012)  
                        - Iroko Cardio: Tirolbiban (2012)  
                        - Regeneron: PCSK9 inhibitor (2012-2013)  
                        - Roche Pharma: PPAR antagonist (2012-2013)  
                        - Accumetrics: VerifyNow device (2012-2013)  
                        - Sanofi Aventis: PCSK9 inhibitor/otamixaban (2013)  

**B - Payment to your Institution:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Daiichi Sankyo: Prasugrel (2012)  
- Eli Lilly: Prasugrel (2012)  
- Accumetrics: VerifyNow device (2012-2013)  

**D - Research funding (departmental or institutional).**  
- Eli Lilly: Prasugrel (2012)
## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Accumetrics : VerifyNow (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Ticagrelor (2012-2013)</td>
</tr>
<tr>
<td>Valgimigli Marco</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Accumetrics : Platelet Function Assay (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Medtronic : stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott Laboratories : stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott Vascular : stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Cordis : stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- CID : stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Chiesi Pharma : tirofiban (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Terumo Inc : Interventional cardiology (2012-2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : ticagrelor (2012-2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Iroko Cardio : Tirofiban (2012-2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Alvimedical : stent (2014)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Anti-thrombotic in ACS (2014)</td>
</tr>
<tr>
<td>Windecker Stephan</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Biosensors : Stent (2012)</td>
</tr>
<tr>
<td></td>
<td>- Boston Scientific : Stent (2012)</td>
</tr>
<tr>
<td></td>
<td>- Cordis : Stent (2012)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Antiplatelet drug (2012-2013)</td>
</tr>
</tbody>
</table>
Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Windecker Stephan</td>
<td>- Eli Lilly: Antiplatelet drug (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott: Stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Medtronic: Stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>- Biotronik: Stent (2012-2013)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Biosensors: Stent (2012)</td>
</tr>
<tr>
<td></td>
<td>- Medtronic: Stent (2012)</td>
</tr>
<tr>
<td></td>
<td>- Cordis: Stent (2012)</td>
</tr>
<tr>
<td></td>
<td>- Medtronic: Stent and Heartvalves (2014)</td>
</tr>
</tbody>
</table>
Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>


### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</td>
</tr>
<tr>
<td>Atalar Enver</td>
<td>Nothing to be declared (2013-2014-2015)</td>
</tr>
<tr>
<td>Averkov Oleg</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- GlaxoSmithKline : Antithrombotic (2013)</td>
</tr>
<tr>
<td></td>
<td>- Medicines Company : Antithrombotic (2013)</td>
</tr>
<tr>
<td></td>
<td>- Krka Pharma : Antithrombotic (2013)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Antithrombotic (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim : Antithrombotic (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Janssen-Cilag : Antithrombotic (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Sanofi Aventis : Antithrombotic (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Bayer Healthcare : Antithrombotic (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Baxter : Esmolol (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Portola Pharmaceuticals : Antithrombotic (2014)</td>
</tr>
<tr>
<td></td>
<td>- Bristol Myers Squibb : Antithrombotic (2014)</td>
</tr>
<tr>
<td></td>
<td>- Apex : Antithrombotic (2014)</td>
</tr>
<tr>
<td></td>
<td>- Sorbent : Heart failure (2014)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Averkov Oleg        | - Sanofi Aventis : Ahtithrombotic (2015)  
- Portola Pharmaceuticals : Ahtithrombotic (2015)  
- Bristol Myers Squibb : Ahtithrombotic (2015)  

**B** - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Sanofi Aventis : Dyslipidemia (2013)  
- Amarin : Dyslipidemia (2013-2014)  
- Novartis : Heart failure (2013-2014)  
- Portola Pharmaceuticals : Antithrombotic (2014)  
- Sorbent : Heart failure (2014)  
- Portola Pharmaceuticals : Ahtithrombotic (2015)  |
| Badimon Lina        | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Sanofi Aventis : cardiovascular (2013)  
- MSD-España : Lipids (2014)  

**D** - Research funding (departmental or institutional).
| Baigent Colin       | **D** - Research funding (departmental or institutional).
# Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
E - Research funding (personal).  
- Novartis: LCZ696 (2013) |
| Bang Lia Evi   | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Amgen: Anti lipid drug (2013)  
- Merck Sharp & Dohme: Anti lipid drug (2013)  
- Astra Zeneca: Anti trombotic (2013)  
- Amgen: Lipid lowering drug (2014)  
- Astra Zeneca: Lipid lowering drug (2014)  
- Merck Sharp & Dohme: Lipid lowering drug (2014)  
- Amgen: Cardiovaskular (2015)  
- Bayer: Cardiovaskular (2015)  
- Sanofi Aventis: Cardiovaskular (2015)  
- GSK: Cardiovaskular (2015)  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Sanofi Aventis: Anti lipid drug (2013)  
- GlaxoSmithKline: Anti lipid drug (2013)  
- Lilly: Anti lipid drug (2013) |
### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Barrabes Jose A      | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Rovi : Antianginal agents (2013)  
- Bayer : Anticoagulant agents (2013)  
**D** - Research funding (departmental or institutional).  
- GlaxoSmithKline : Participation in LATITUDE TIMI 60 study (losmapimod) (2015) |
| Baumgartner Helmut   | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
**B** - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
| Becker David         | Nothing to be declared (2013)  
**A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Bolognese Leonardo| A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
D - Research funding (departmental or institutional).  
| Budaj Andrzej     | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
| Bueno Hector      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- BMS/Pfizer : Apixaban (2013)  
- Roche Pharma : Dalcetrapib (2013)  
- Novartis : Relaxin (2013)  
### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
- Novartis : Serelaxin (2014)  
D - Research funding (departmental or institutional).  
E - Research funding (personal).  
| Carerj Scipione            | Nothing to be declared (2013-2014-2015)                                                                                                                                                                                             |
| Casselman Filip            | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
# Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Cuisset Thomas    | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
|                   |   - Eli Lilly : Antiplatelet (2013)                                                                |
|                   |   - Daiichi Sankyo : Antiplatelet drug (2013)                                                      |
|                   |   - Iroko Cardio : Antiplatelet drug (2013)                                                        |
|                   |   - Biosensors : Device (2013)                                                                    |
|                   |   - Boston Scientific : Device (2013)                                                              |
|                   |   - Terumo Inc : Device (2013)                                                                    |
|                   |   - Abbott Vascular : Device (2013)                                                                |
|                   | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
|                   | D - Research funding (departmental or institutional).                                               |
|                   |   - Eli Lilly : Medications (2013)                                                                 |
### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eftychiou Christos</td>
<td>Nothing to be declared (2013-2014-2015)</td>
</tr>
</tbody>
</table>
| Erol Cetin                                 | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
**B - Payment to your Institution:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
| Etriby Adel Mohamad Kamal                  | Nothing to be declared (2013-2014-2015)                                                                                                                                                                                                                 |
| Fitzsimons Donna                          | Nothing to be declared (2013-2015)                                                                                                                                                                                                                     |
|                                           | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Amgen : FH Treatment options (2014)                                                                                                                                                          |
| Gaemperli Oliver                          | Nothing to be declared (2013)                                                                                                                                                                                                                         |
|                                           | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Biosensors : Stents (2014)  
- Biosensors : Travel Grant to AsiaPCR 2015 (2015)                                                                                                                                          |
| Ginghina Carmen                           | Nothing to be declared (2013-2015)                                                                                                                                                                                                                     |
|                                           | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- LABORMED ALVOGEN ("Tabloul clinic al arteriopatiei periferice") - ALFA WASSERMMAN ("Medicatia in arteriopatiile periferice – Vessel Due")  
- LABORMED ALVOGEN ("Tabloul clinic al arteriopatiei periferice") - ALFA WASSERMMAN ("Medicatia in arteriopatiile periferice – Vessel Due") (2014)                                              |
| Grosu Aurel                               | Nothing to be declared (2013-2014-2015)                                                                                                                                                                                                                 |
| Gudnason Thorarinn                         | Nothing to be declared (2015)                                                                                                                                                                                                                         |
|                                           | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Pfizer : NOAC (2014)  
**E - Research funding (personal).**  
- Novartis : Heart failure (2013)                                                                                                                                                              |
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Halle Martin            | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Novartis : transplantation (2013)  
- Roche Pharma : diabetes, dyslipidemia (2013-2014)  
- Pfizer : coagulation (2015)  
- Roche Pharma : diabetes (2015)  
- Techniker Krankenkasse : health insurance company (2015)  

**B - Payment to your Institution:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  

| Hamm Christian          | **A - Direct Personal payment:** Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Iroko Cardio : drugs (2013)  
- Roche Diagnostics : marker (2013)  
- Medtronic : PCI (2013)  

27/08/2015
<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>

D - Research funding (departmental or institutional).
---

**Guidelines on NSTE-ACS (version 2015) - Reviewers**

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Held Claes      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
|                 | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
|                 | - Roche Diagnostics : cardiology (2013-2014)                                                   |
| Hildick-Smith David | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
|                 | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
|                 | C - Receipt of royalties for intellectual property.                                                |
|                 | D - Research funding (departmental or institutional).                                             |
| Huber Kurt      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  

27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iliodromitis Efstatios</td>
<td>Nothing to be declared (2013-2014-2015)</td>
</tr>
</tbody>
</table>
| James Stefan          | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
                        |   - Sanofi Aventis : coagulation inhibition (2013-2014)                                            |
|                       |   - Medtronic : Stents and valves (2013-2014)                                                     |
|                       | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
                        |   - Eli Lilly : platelet inhibition (2013-2014)                                                   |
|                       |   - Terumo Inc : thrombus asp catheter (2013-2014)                                                |
|                       | D - Research funding (departmental or institutional).                                               |
| Kedev Sasko           | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
                        |   - Medtronic : Honaria (2013)                                                                    |
|                       |   - Abbott Vascular : Speaker fees (2013)                                                          |
|                       |   - Meril : Speaker fees (2014)                                                                   |
|                       |   - Terumo Inc : Speaker fees (2015)                                                               |
### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koning Rene</td>
<td>Nothing to be declared (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Lilly : cardiology (2015)</td>
</tr>
<tr>
<td></td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Committee Member of CFCI (congres francophone Paris) : CARDIOLOGY (2015)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Biosensors : CARDIOLOGY (2015)</td>
</tr>
<tr>
<td></td>
<td>- Biotronik : CARDIOLOGY (2015)</td>
</tr>
<tr>
<td></td>
<td>- Braun : CARDIOLOGY (2015)</td>
</tr>
<tr>
<td>Larsen Alf Inge</td>
<td>Nothing to be declared (2013-2014-2015)</td>
</tr>
<tr>
<td>Latkovskis Gustavs</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Sanofi Aventis : Antiplatelets (2013)</td>
</tr>
<tr>
<td></td>
<td>- Takeda Pharmaceuticals : Cardiovascular risk (2013)</td>
</tr>
<tr>
<td></td>
<td>- Novo-Nordisk : Diabetes (2013)</td>
</tr>
<tr>
<td></td>
<td>- Servier : Hypertension (2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott Laboratories : lipid-lowering drugs (2013)</td>
</tr>
<tr>
<td></td>
<td>- GlaxoSmithKline : LPH (2013)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : Dyslipidemias, anticoagulants (2013-2014)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
D - Research funding (departmental or institutional).  
- Latvian Council of Science: Genetics of CVD (2013)  
- Latvian Council of Science: Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia (2015)  
E - Research funding (personal).  
- Bayer: Anticoagulation (2013)  
- Pharma and Chemistry Competence Centre of Latvia: Statin myopathy (2014-2015) |
| Lewis Basil S      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Sanofi Aventis: Anti-diabetics (2013)  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- GlaxoSmithKline: Anti-atherosclerosis (2013)  
- Daiichi Sankyo: Diabetes, antithrombotics (2013)  
- Eli Lilly: Heart failure (2013) |
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewis Basil S</td>
<td>- Sanofi Aventis: Lipidology (2013)</td>
</tr>
<tr>
<td>Lip Gregory Y H</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astellas: atrial fibrillation, thrombosis (2013)</td>
</tr>
<tr>
<td></td>
<td>- Roche Diagnostics: anticoagulation (2015)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Bayer: atrial fibrillation, thrombosis (2013)</td>
</tr>
<tr>
<td>Marandi Toomas</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Portola Pharmaceuticals: Betrixaban, investigator (2013-2014)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matetzky Shlomi</td>
<td>Nothing to be declared (2013-2014-2015)</td>
</tr>
<tr>
<td>Milicic Davor</td>
<td><strong>A - Direct Personal payment:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim : cardiovascular drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : cardiovascular drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Sanofi Aventis : cardiovascular drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Krka Pharma : cardiovascular drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Pliva, : cardiovascular drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Thoratec : mechanical circulatory support (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Marck Medical : mechanical circulatory support (2013-2014)</td>
</tr>
<tr>
<td></td>
<td><strong>D - Research funding (departmental or institutional).</strong></td>
</tr>
<tr>
<td></td>
<td>- University of Zagreb : Antithrombotic drugs (2015)</td>
</tr>
<tr>
<td></td>
<td><strong>E - Research funding (personal).</strong></td>
</tr>
<tr>
<td></td>
<td>- University of Zagreb : Platelet reactivity to antithrombotic drugs (2013-2014)</td>
</tr>
<tr>
<td>Mimoso Jorge M Vieira</td>
<td><strong>A - Direct Personal payment:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Servier : Ivabradine (2013)</td>
</tr>
<tr>
<td></td>
<td>- JaBA Recordati : Pitavastatine (2014)</td>
</tr>
<tr>
<td></td>
<td>- Bayer : Xarelto (2014)</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim : Dabigatran (2015)</td>
</tr>
<tr>
<td></td>
<td><strong>B - Payment to your Institution:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Ticagrelor (2013)</td>
</tr>
<tr>
<td>Mussagaliyeva Aisulu</td>
<td><strong>A - Direct Personal payment:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Servier : Stable angina (2013-2014)</td>
</tr>
</tbody>
</table>

27/08/2015
Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Mussagaliyeva Aisulu    | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
| Neumann Franz Josef     | B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
D - Research funding (departmental or institutional):  
| Parkhomenko Alexander   | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Servier : trimetazidin, rivaroxaban, ticagrelor (2013-2014)  
- Servier : trimetazidine (2015) |
Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Parkhomenko Alexander         | **B** - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
  - Bayer : rivaroxabane (2013-2014)  
  **C** - Receipt of royalties for intellectual property.  
  - BHFZ : corvitine (2013-2014)  
  **D** - Research funding (departmental or institutional).  
  - European Research Foundation FP7 : biomarkers (2015) |
| Pereira Bruno                 | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
  - Astra Zeneca : Speaker Fees (2014)  
  - Abbott Vascular : Speaker Fees (2014)  
| Peters Ron J G                | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
  - Boehringer-Ingelheim : anticoagulants (2014)  
  - Daiichi Sankyo : antiplatelet agents (2014)  
  - Amgen : lipid lowering (2014)  
  - Sanofi Aventis : lipid lowering (2014)  
  - Merck Sharp & Dohme : lipid lowering (2014)  
  - Astrazeneca : lipid lowering (2014)  
  - Sanofi Aventis : alirocumab (2015)  
  - Astrazeneca : ticagrelor (2015)  
  **D** - Research funding (departmental or institutional).  
  - Philips Healthcare : DirectLife activity program (2015)  
  - weight watchers international : weight reduction and physical fitness (2015) |
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Pietila Mikko Juhani     | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- St Jude Medical : Invasive cardiology (2013)  
- Pfizer : Secondary prevention (2013)  
- Servier : Heart failure (2014)  
| Postadzhiyan Arman       | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Pfizer : AF (2015)  
- Servier : arterial hypertension (2015)  
- Berlin Menarini : arterial hypertension (2015)  
- Sanofi Aventis : lipids (2015)                                                                                                                                                                                                                                                                                     |
| Richter Dimitrios        | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Menarini : CAD (2013)  
Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Actavis: Lipids, thrombosis (2015)</td>
</tr>
<tr>
<td>Rickli Hans</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim: Dabigatran (2013)</td>
</tr>
<tr>
<td></td>
<td>- Daiichi Sankyo: Prasugrel (2013-2014)</td>
</tr>
<tr>
<td>Rosemann Thomas</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Menarini: general internal medicine (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Novartis: Lecture about personalized medicine (2014)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
</tbody>
</table>

27/08/2015
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sechtem Udo</td>
<td><strong>A - Direct Personal payment:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : Drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td><strong>B - Payment to your Institution:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Berlin Chemie AG : Drugs (2013)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : Drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Siemens Healthcare : Drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Bayer Vital : Drugs (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Berlin Chemie AG : cath lab equipment (2014)</td>
</tr>
<tr>
<td></td>
<td>- Bristol Myers Squibb : Drugs (2015)</td>
</tr>
<tr>
<td>Serpytis Pranas</td>
<td><strong>D - Research funding (departmental or institutional).</strong></td>
</tr>
<tr>
<td>Sinnaeve Peter R</td>
<td><strong>B - Payment to your Institution:</strong> Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : ACS (2013)</td>
</tr>
<tr>
<td></td>
<td>- GlaxoSmithKline : ACS &amp; CAD (2013)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td>Steg Philippe Gabriel</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2013)</td>
</tr>
<tr>
<td></td>
<td>- Vivus : Drugs for obesity (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Regado Biosciences : Steering Committee for trial of anticoagulant (2014)</td>
</tr>
</tbody>
</table>
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
- Pfizer : Events adjudication committee (2015)  
- CSL Behring : lipid lowering drugs (2015)  
C - Receipt of royalties for intellectual property.  
D - Research funding (departmental or institutional).  
| Studencan Martin              | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
  - GlaxoSmithKline : Dabigatran (2013)  
| Swanson Neil                  | Nothing to be declared (2013)  
D - Research funding (departmental or institutional).  
| Terzic Ibrahim                | Nothing to be declared (2013-2014)  
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
  - Servier : Preduktal - Investigator in ATPCI study (2015)  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
  - Sadra Medical : Odyssey study (2015) |
| Tsioufis Costas               | Nothing to be declared (2013)  
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- St Jude Medical : Honoraria, Travel Expenses (2014-2015)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- St Jude Medical : Renal denervation (2014-2015)</td>
</tr>
<tr>
<td>Vrints Christian Joseph Marie</td>
<td>Nothing to be declared (2015)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Medtronic : pacing, ICD &amp; stents (2013-2014)</td>
</tr>
<tr>
<td>Weidinger Franz</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Bayer Healthcare : Rivaroxaban (2013)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Ticagrelor, Saxagliptin (2013)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : Apixaban (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Daiichi Sankyo : Antiplatelet therapy (2013)</td>
</tr>
<tr>
<td></td>
<td>- Merck Sharp &amp; Dohme : Lipid lowering (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Biotronik : Drug-eluting stent (2014)</td>
</tr>
</tbody>
</table>
## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
D - Research funding (departmental or institutional).  
| Widimsky Petr | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Sanofi Aventis: Antithrombotic agents (2013-2014)  
| Zamorano Gomez Jose Luis | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Daiichii: Atrial Fib (2013)  
- Philips: 3D echo (2014)  
- Toshiba medical imaging: fusion imaging 3D echo CT (2014)  
- Astra Zeneca: Speaker fee for 1 talk in 2014 (2014)  
- Pfizer: Lecturing (2015)  
- Sorin Group: Respocardia echo protocol (2015) |
### Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Zamorano Gomez Jose Luis    | **B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.**  
- European Research FP7 : CV Imaging (2013)  
- Servier : Imaging in ISchemic patients (2013)  
- Siemens Healthcare : 3d echo software and free style echo (2014-2015)  
**C - Receipt of royalties for intellectual property.**  
**D - Research funding (departmental or institutional).**  
- Ikaria : Clinical trial (2014-2015) |
Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aboyans Victor</td>
<td>Nothing to be declared (2013)</td>
</tr>
<tr>
<td></td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca: Antithrombotics (2014)</td>
</tr>
<tr>
<td></td>
<td>- Sanofi Aventis: Hyperlipidemia (2014)</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim: Oral anticoagulation (2014)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer/BMS alliance: Oral anticoagulation (2014)</td>
</tr>
<tr>
<td>Achenbach Stephan</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Bayer: Anticoagulation (2013)</td>
</tr>
<tr>
<td></td>
<td>- Behring: Anticoagulation (2013)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca: Antiplatelet Therapy (2013)</td>
</tr>
<tr>
<td></td>
<td>- Abbott: Coronary Intervention (2013)</td>
</tr>
<tr>
<td></td>
<td>- Siemens Healthcare: CT (2013)</td>
</tr>
<tr>
<td></td>
<td>- Servier: Imaging (2013)</td>
</tr>
<tr>
<td></td>
<td>- Guerbet: Imaging (2013)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Abbott: Coronary Intervention (2013-2014)</td>
</tr>
<tr>
<td>Agewall Stefan</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Böhringer Ingelheim: Anticoagulatn treatment (2013)</td>
</tr>
<tr>
<td></td>
<td>- Roche Diagnostics: Cardiac markers (2013)</td>
</tr>
<tr>
<td></td>
<td>- Orion: Heart failure (2013)</td>
</tr>
</tbody>
</table>
# Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Agewall Stefan              | - Pfizer : Lipids (2013)  
                            | - Sanofi Aventis : Lipids (2013)  
                            | - Siemens Healthcare : Markers (2013)  
                            | - Thermo Fischer Scientific : Cardiac markers (2014-2015) |
| Badimon Lina                | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
                            | - Sanofi Aventis : cardiovascular (2013)  
                            | - MSD-España : Lipids (2014)  
                            | D - Research funding (departmental or institutional).  
| Baron Esquivias Gonzalo     | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
                            | D - Research funding (departmental or institutional).  
                            | - Biotronik : Vasovagal syncope & Pacing (2013)  
### Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Baumgartner Helmut| A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
| Bax Jeroen        | Nothing to be declared (2014-2015)  
D - Research funding (departmental or institutional).  
- Servier : Farma (2013)  
- Lantheus Inc : Imaging (2013)  
- Boston Scientific : Pacing (2013)  
- Medtronic : Pacing (2013)  
- St Jude Medical : Pacing (2013)  
- Biotronik : Pacing (2013) |
| Bueno Hector      | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- BMS/Pfizer : Apixaban (2013) |
<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| Bueno Hector          | - Roche Pharma : Dalcetrapib (2013)  
- Novartis : Relaxin (2013)  
- Novartis : Serelaxin (2014)  
D - Research funding (departmental or institutional).  
E - Research funding (personal).  
| Carerj Scipione       | Nothing to be declared (2013-2014-2015)                                                                                                                                 |
| Erol Cetin            | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
**Committee for Practice Guidelines 2014-2016 - MEMBERS**

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fitzsimons Donna</td>
<td>Nothing to be declared (2013-2015)</td>
</tr>
<tr>
<td></td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Amgen : FH Treatment options (2014)</td>
</tr>
<tr>
<td>Gaemperli Oliver</td>
<td>Nothing to be declared (2013)</td>
</tr>
<tr>
<td></td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Biosensors : Stents (2014)</td>
</tr>
<tr>
<td></td>
<td>- Biosensors : Travel Grant to AsiaPCR 2015 (2015)</td>
</tr>
<tr>
<td>Kirchhof Paulus</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
</tbody>
</table>
Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kirchhof Paulus</td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim : cardiovascular (2013)</td>
</tr>
<tr>
<td></td>
<td>- Gilead : cardiovascular (2013)</td>
</tr>
<tr>
<td></td>
<td>- BMS / Pfizer alliance : cardiovascular (2013)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)</td>
</tr>
<tr>
<td>Kolh Philippe H</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- B.Braun : Surgical instruments (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- St Jude Medical : Cardiac valves (2013)</td>
</tr>
<tr>
<td></td>
<td>- Boston Scientific : Coronary stents (2013)</td>
</tr>
<tr>
<td></td>
<td>- Siemens Healthcare : Medical imaging (2013)</td>
</tr>
<tr>
<td></td>
<td>- Johnson &amp; Johnson : Thoracoscopic devices (2013)</td>
</tr>
</tbody>
</table>
Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lancellotti Patrizio</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Servier : Heart Failure (2013)</td>
</tr>
<tr>
<td></td>
<td>- Menarini : nebivolol (2014)</td>
</tr>
<tr>
<td></td>
<td>- St Jude Medical : Heart Failure (2015)</td>
</tr>
<tr>
<td></td>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Astrazeneca : Dyslipidemia (2013)</td>
</tr>
<tr>
<td></td>
<td>- Boston Scientific : CRT (2014)</td>
</tr>
<tr>
<td></td>
<td>- Servier : procoralan (2014)</td>
</tr>
<tr>
<td></td>
<td>- Daiichi Sankyo : Teaching course on imaging (2015)</td>
</tr>
<tr>
<td></td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Roche Diagnostics : anticoagulation (2015)</td>
</tr>
</tbody>
</table>
**Committee for Practice Guidelines 2014-2016 - MEMBERS**

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lip Gregory Y H</td>
<td>D - Research funding (departmental or institutional).</td>
</tr>
<tr>
<td></td>
<td>- Bayer : atrial fibrillation, thrombosis (2013)</td>
</tr>
<tr>
<td>Nihoyannopoulos Petros</td>
<td>Nothing to be declared (2014-2015)</td>
</tr>
<tr>
<td></td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- GSK : Consultant for Imaging studies (2013)</td>
</tr>
<tr>
<td>Ponikowski Piotr</td>
<td>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
</tr>
<tr>
<td></td>
<td>- Bayer : anticoagulant (2013)</td>
</tr>
<tr>
<td></td>
<td>- Bristol Myers Squibb : anticoagulant (2013)</td>
</tr>
<tr>
<td></td>
<td>- ROSCHE : diabetes (2013)</td>
</tr>
<tr>
<td></td>
<td>- Boehringer-Ingelheim : anticoagulant (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Respicardia : anticoagulant (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Johnson &amp; Johnson : heart failure (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : heart failure, anticoagulant (2013-2014)</td>
</tr>
<tr>
<td></td>
<td>- MSD : lipids (2014)</td>
</tr>
</tbody>
</table>
Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
- Vifor Pharma ltd : heart failure (2014)
- MSD : lipids (2014)

D - Research funding (departmental or institutional).
- Vifor Pharma ltd : heart failure (2013)
- Singulex : biomarkers (2015)
### Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
| **Roffi Marco**               | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Daiichi Sankyo : antiplatelet therapy (2013)  
- Lilly : antiplatelet therapy (2013)  
- AstraZeneca : antiplatelet therapy (2013)  
- Johnson & Johnson : coronary catheters (2014)  
**D** - Research funding (departmental or institutional).  
| **Torbicki Adam**             | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)  
**B** - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
| **Vaz Carneiro Antonio**      | Nothing to be declared (2015)  
**B** - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- AbbVie : Oncology (2013-2014) |
| **Windecker Stephan**         | **A** - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Eli Lilly : Antiplatelet drug (2013)  
**B** - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- AbbVie : Oncology (2013-2014)  

27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
</table>
- Medtronic : Stent (2013)  
- Biotronik : Stent (2013)  
D - Research funding (departmental or institutional).  
- Medtronic : Stent and Heartvalves (2014)  
| Zamorano Gomez Jose Luis | A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  
- Daiichii : Atrial Fib (2013)  
Z - Research funding (departmental or institutional).  
<table>
<thead>
<tr>
<th>Expert</th>
<th>Type of Relationship with Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zamorano Gomez Jose Luis</td>
<td>- Philips : 3D echo (2014)</td>
</tr>
<tr>
<td></td>
<td>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</td>
</tr>
<tr>
<td></td>
<td>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</td>
</tr>
<tr>
<td></td>
<td>- Pfizer : Lecturing (2015)</td>
</tr>
<tr>
<td>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</td>
<td>- European Research FP7 : CV Imaging (2013)</td>
</tr>
<tr>
<td></td>
<td>- Servier : Imaging in ISchemic patients (2013)</td>
</tr>
<tr>
<td></td>
<td>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</td>
</tr>
<tr>
<td></td>
<td>- Ikaria : Clinical trial (2014-2015)</td>
</tr>
</tbody>
</table>